Obesity Medicine

Three-quarters of primary care survey respondents prescribe GLP-1 RAs for weight loss and half get questions daily about the drugs. See all the results.

Caissa Troutman, MD, provides an overview of the connection between obesity and hypertension.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

In a study of adolescents with obesity, those in the GLP-1RA group had a 33% lower risk of experiencing suicidal ideation or attempts compared with matched controls.

Obesity is a complex disease that requires a multispecialty approach to address the physical and also the mental and emotional components of the widespread disorder.

Your daily dose of the clinical news you may have missed.

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

Your daily dose of the clinical news you may have missed.

In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.

Vials of tirzepatide 2.5 mg and 5 mg will be available with a prescription for the labeled drug through LillyDirect after completing a multistep verification process, the company said.

Patients with obesity face both physical and emotional challenges during the COVID-19 pandemic. How can PCPs help?

Anila Chadha, MD, talks to Patient Care about how antiobesity medications can aid in reducing CVD risk in patients with obesity.

Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Anila Chadha, MD, highlights key preventive strategies to reduce CVD risk in patients with obesity and how to tailor them to address individual patient needs.

Your daily dose of the clinical news you may have missed.

Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.

Semaglutide bought online without a prescription were unregistered, contaminated, and had levels of product that exceeded labeled amount, according to new data.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..

The significant rise in new GLP-1 RA prescriptions between 2011 and 2023 saw a doubling in the proportion written for obesity and a decline in those for T2D.

Your daily dose of the clinical news you may have missed.

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.

Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.

The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.